02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 44.48
−1.29%Oct 22, 2026, 10:25 UTC
Southbound Stock Connect flows recorded a net inflow of HK$489 million into Tencent Holdings Ltd. and net outflows of HK$1.677 billion from Alibaba Group Holding Ltd., HK$911 million from SMIC and HK$642 million from WuXi Biologics (Cayman), Inc..
Source:Oct 22, 2026, 04:12 UTC
Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.
Oct 20, 2026, 08:12 UTC
Hong Kong-listed shares had mixed moves, including Alibaba down 3.6% and Lenovo Group Ltd. down 10%, while Hansoh Pharmaceutical rose 8.3%; Luxxu Group Ltd. and Chervon Holdings Ltd. reached record highs.
Source:Oct 20, 2026, 04:34 UTC
Transcenta Holding Ltd. received the first net-of-tax installment of RMB 95 million from WuXi Biologics (Cayman), Inc. for the sale of its CDMO assets.
Source:Oct 20, 2026, 04:12 UTC
Hong Kong stocks fell in the half-day session, with the Hang Seng Index down 1.0% to 23,956, the Hang Seng Tech Index down 1.2% to 4,058, and the Hang Seng China Enterprises Index down 0.9% to 8,055.
Source:Oct 16, 2026, 10:25 UTC
Southbound Stock Connect flows showed a net inflow of HK$388 million into Tencent Holdings Ltd. and net outflows of HK$668 million from WuXi Biologics (Cayman), Inc., HK$506 million from Xiaomi Corp. and HK$305 million from Kingboard Laminates Holdings Ltd..
Source:Oct 16, 2026, 01:52 UTC
Hong Kong stocks rose more than 300 points in early trading to 24,392.3, while the Hang Seng Tech Index gained as much as 2.24% to 4,152, with Alibaba and biotechnology shares among the gainers.
Oct 13, 2026, 04:12 UTC
Hong Kong-listed shares of Hua Hong Semiconductor fell 5.5% to HK$84.95, Haidilao fell 4.7% to HK$9.135, WuXi Biologics (Cayman), Inc. fell 4.4% to HK$50.35, and JD.com, Inc. fell 3.7% to HK$104.50; Bank of Communications and China Merchants Bank were unchanged at HK$8.585 and HK$53.80, respectively, both at record highs.
Source:Oct 9, 2026, 09:50 UTC
AIA Group Ltd. recorded net purchases of HK$291 million in Hong Kong-listed shares, including HK$1.066 billion of AIA, and net sales of several other securities.
Source:Oct 9, 2026, 04:12 UTC
Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. rising 7.2% to HK$25.36 and several other active stocks moving higher or lower.
Source:Oct 9, 2026, 01:36 UTC
WuXi Biologics (Cayman), Inc. shares fell as much as 3.7% after a pre-market block trade of 90 million shares at HK$52.31 each, 3.3% below the previous close.
Source:Oct 7, 2026, 01:37 UTC
Hong Kong stocks opened lower, with the Hang Seng Index down 108 points (0.45%), the Hang Seng Tech Index down 13 points (0.33%) and the Hang Seng China Enterprises Index down 33 points (0.42%).
Oct 6, 2026, 08:12 UTC
Hong Kong stocks closed higher on October 6, 2026, with the Hang Seng Index up 240 points (1.0%) at 24,280, the Hang Seng Tech Index up 39 points (0.9%) at 4,223, and the China Enterprises Index up 77 points (1.0%) at 8,128 on turnover of HK$98.265 billion.
Oct 2, 2026, 04:12 UTC
Hong Kong stocks fell in the morning session on October 2, 2026, with the Hang Seng Index down 648 points (2.6%) to 23,964 and the Hang Seng Tech Index down 104 points (2.4%) to 4,149, while Central New Energy hit a record high, up 10.5%.
Sep 30, 2026, 10:25 UTC
Southbound Stock Connect investors recorded a net inflow of HK$1.407 billion into Tencent, HK$179 million into WuXi Biologics and HK$167 million into MINIMAX-W, while recording net outflows of HK$971 million from SMIC, HK$146 million from Zhipu and HK$17.16 million from Akeso.
Source:Sep 30, 2026, 08:12 UTC
Hong Kong stocks closed higher on September 30, 2026, with the Hang Seng Index up 89 points or 0.4% at 24,613 and the Hang Seng Tech Index up 4 points or 0.1% at 4,253, on turnover of HK$187.158 billion.
Sep 21, 2026, 02:51 UTC
Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.
Source:Sep 21, 2026, 02:12 UTC
Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.
Source:Sep 16, 2026, 13:11 UTC
WuXi Biologics signed an agreement to land a commercial high-end manufacturing platform project in Wuxi, including new biologic drug production lines and supporting process development laboratories.
Source:Aug 27, 2026, 08:31 UTC
WuXi Biologics management raised its full-year 2026 revenue growth guidance to 20%-23% year-over-year on a constant currency basis, up from the previous 16%-20% guidance.
Source:Aug 25, 2026, 09:56 UTC
WuXi Biologics reported first-half results with revenue up 18.4% year-on-year to RMB 11.787 billion, gross profit up 28.1% to RMB 5.448 billion, and net profit up 5.8% to RMB 2.916 billion.
Aug 6, 2026, 23:32 UTC
Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.
Source:Jul 4, 2026, 11:52 UTC
Hong Kong-listed companies, led by Tencent Holdings, AIA Group, and Xiaomi Corporation, have conducted share buybacks totaling over 900 billion Hong Kong dollars year-to-date, with June 2026 reaching a monthly record of over 300 billion Hong Kong dollars.
Jun 18, 2026, 05:00 UTC
WuXi Biologics' Suzhou Biosafety Testing Center received its fourth EMA GMP certification, enabling 19 commercial products for the European market.
Source:Jun 5, 2026, 02:45 UTC
WuXi Biologics completed the topping-out of a drug product facility at its Singapore CRDMO Hub.
Source: